SAN FRANCISCO – Although most of the biotech world is starting the week with a J.P. Morgan Healthcare Conference hangover, it's business as usual for the redoubtable Steve Burrill, whose life sciences venture firm, Burrill & Co., recently added Capital Fund IV to its portfolio.